129 related articles for article (PubMed ID: 1848996)
1. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
Osterlind K; Hansen M; Hirsch FR; Dombernowsky P; Sörenson S; Pedersen AG; Hansen HH
Ann Oncol; 1991 Jan; 2(1):41-6. PubMed ID: 1848996
[TBL] [Abstract][Full Text] [Related]
2. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
[TBL] [Abstract][Full Text] [Related]
3. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
[TBL] [Abstract][Full Text] [Related]
4. Etoposide versus methotrexate in small cell bronchial carcinoma. A randomized study of two types of four-drug chemotherapy regimens.
Nõu E; Lamberg K; Brodin O
Acta Oncol; 1992; 31(8):853-60. PubMed ID: 1337833
[TBL] [Abstract][Full Text] [Related]
5. Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial.
Havemann K; Wolf M; Holle R; Gropp C; Drings P; Manke HG; Hans K; Schroeder M; Heim M; Victor N
Cancer; 1987 Mar; 59(6):1072-82. PubMed ID: 3028596
[TBL] [Abstract][Full Text] [Related]
6. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification.
Broder LE; Sridhar KS; Selawry OS; Charyulu KN; Rao RK; Saldana MJ; Donnelly EJ; Raub WA
Am J Clin Oncol; 1994 Dec; 17(6):527-37. PubMed ID: 7977175
[TBL] [Abstract][Full Text] [Related]
7. Alternating chemotherapy with or without VP-16 in extensive-stage small-cell lung cancer.
Everson LK; Jett JR; O'Fallon JR; Krook JE; Dalton RJ; Mailliard JA; Tschetter LK; Cullinan SA; Gerstner JB; Morton RF
Am J Clin Oncol; 1989 Aug; 12(4):339-44. PubMed ID: 2547304
[TBL] [Abstract][Full Text] [Related]
8. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group.
Lebeau B; Chastang C; Allard P; Migueres J; Boita F; Fichet D
Eur Respir J; 1992 Mar; 5(3):286-90. PubMed ID: 1315294
[TBL] [Abstract][Full Text] [Related]
9. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
10. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up.
Lassen U; Kristjansen PE; Osterlind K; Bergman B; Sigsgaard TC; Hirsch FR; Hansen M; Dombernowsky P; Hansen HH
Ann Oncol; 1996 Apr; 7(4):365-71. PubMed ID: 8805928
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
Aisner J; Whitacre M; Van Echo DA; Wiernik PH
Cancer Treat Rep; 1982 Feb; 66(2):221-30. PubMed ID: 6275987
[TBL] [Abstract][Full Text] [Related]
12. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
14. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
15. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens.
Nõu E; Brodin O; Bergh J
Cancer; 1988 Sep; 62(6):1079-90. PubMed ID: 2457422
[TBL] [Abstract][Full Text] [Related]
17. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
Navarro M; Mur E; Jolis L; Bellmunt J; Bodi R; Solé LA; Rubio D
Rev Clin Esp; 1991 Oct; 189(5):209-12. PubMed ID: 1666192
[TBL] [Abstract][Full Text] [Related]
18. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
19. The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients.
Hirsch FR; Hansen HH; Hansen M; Osterlind K; Vindeløv LL; Dombernowsky P; Sørensson S
J Clin Oncol; 1987 Apr; 5(4):585-91. PubMed ID: 3031225
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study.
Wampler GL; Heim WJ; Ellison NM; Ahlgren JD; Fryer JG
J Clin Oncol; 1991 Aug; 9(8):1438-45. PubMed ID: 1649265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
